VivoSeq
Other

Newly Diagnosed

4

Pipeline Programs↗

96

Active Trials↗

19

Companies Involved↗

Newly Diagnosed is an early-stage landscape with 4 programs across 19 companies. The most active players are Johnson & Johnson, Takeda, Jazz Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

47/100

Mech. Concentration

33/100

Completion Rate

66/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 1Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 2Novartis logo

Novartis

0 programs

PreclinicalP

Princess Maxima Center for Pediatric Oncology

0 programs

PreclinicalA

Aptevo Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 13

Daratumumab

Johnson & Johnson

Dexamethasone

Aspen Global Incorporated

Ixazomib

Takeda

Phase 21

CPX-351

Jazz Pharmaceuticals

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

200

clinical trials

Recruiting56 · 28%
Completed42 · 21%
Unknown status39 · 20%
Active, not recruiting21 · 11%
Not yet recruiting18 · 9%
Terminated15 · 8%
Other9 · 5%

Clinical Trials

Trial Activity

200 trials

Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 1·NCT06651866·18 enrolled
Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients.
Recruiting·TThe Searle Company Limited Pakistan·N/A·NCT06625346·420 enrolled
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Recruiting·Children's Oncology Group·Phase 3·NCT04293562·1,186 enrolled
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
Recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 3·NCT06187441·599 enrolled
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT07172204·25 enrolled
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
Recruiting·OOncoVerity, Inc.·Phase 2·NCT06384261·120 enrolled
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
Recruiting·TTechnische Universität Dresden·Phase 2·NCT05904106·146 enrolled
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06429098·40 enrolled
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 3·NCT05994690·905 enrolled
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07410520·50 enrolled
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Recruiting·YYan Zhang, MD·Phase 2·NCT06176729·30 enrolled
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 2·NCT06262438·60 enrolled
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06621199·42 enrolled
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05558124·18 enrolled
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Recruiting·HHuazhong University of Science and Technology·Phase 2·NCT06005870·41 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)